Skip to main content
. 2016 Aug 22;7(51):84003–84016. doi: 10.18632/oncotarget.11510

Figure 1. Oncogene mutation status and immunostaining of TP53 and CTNNB1.

Figure 1

A. Mutation at nucleotide 35 of the KRAS gene (G > A) is representatively shown. BRAF mutation was not detected in any FAP tumor samples. B. Immunostaining of TP53. When nuclear staining was present in tumor cells, TP53 mutation was considered as positive. C. Immunostaining of CTNNB1. A case with cellular membrane staining, i.e. CTNNB1-activation(-) (left), and a case with nuclear and cytoplasmic staining, i.e. CTNNB1-activation(+) (right), are representatively shown.